Stamford, CT -- (SBWIRE) -- 12/07/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Orexigen Therapeutics, Inc. (NASDAQ:OREX), Noodles & Co (NASDAQ:NDLS), Molycorp Inc (NYSE:MCP), Keryx Biopharmaceuticals (NASDAQ:KERX)
Orexigen Therapeutics, Inc. (NASDAQ:OREX) ended higher +0.88% from its previous close of $5.68 and complete the day at $5.73. The total number of shares changed hands during the day was 4.15 million. After opening at $5.75, the stock hit as high as $5.79. However, it traded between $4.54 and $7.84 over the last twelve months.
Stocks graphical chart shows a bullish trend during its last one month’s trading session. It remained negative -16.23% during the previous three months trade. Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include Contrave, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic, which has completed Phase II clinical trials. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in the United States, Canada, and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
For How Long OREX will Fight for Profitability? Read This Trend Analysis report
Noodles & Co (NASDAQ:NDLS) closed yesterday at $37.70, a -6.06% decrease. Around 4.10 million shares were traded, beating an-average trading volume of 233,997 shares. The company is now valued at around $873.97 million. The stock opened the session at $39.18 and touched its highest price point at $39.60.
NDLS’s lowest price point for the session stood at $37.48 and its 52 week price range stood at $32.00 - $51.97. Noodles & Company develops and operates fast casual restaurants. The company?s restaurants provide noodle and pasta dishes, soups, salads, and sandwiches. As of May 28, 2013, it had 343 restaurants, including 291 company-owned and 52 franchised locations in 26 states and the District of Columbia. The company was founded in 1995 and is based in Broomfield, Colorado.
Has NDLS Found The Bottom And Ready To Gain Momentum? Find Out Here
Molycorp Inc (NYSE:MCP) moved -3.43 percent lower at $4.78 and traded between $4.76 and $5.03 after opening the day at $5.00. Going back further than one month, 1-year performance after recent close was -49.36%.
The company has a total of 240.37 million outstanding shares and its total market capitalization is $1.15 billion. Its beta value stands at 3.25 times and earnings per share was -$3.85. Molycorp, Inc. produces and sells rare earth and rare metal materials in the United States and internationally. The company?s Resources segment extracts rare earth minerals, including rare earth concentrates; rare earth oxides (REO), such as lanthanum, cerium, neodymium, praseodymium, and yttrium; heavy rare earth concentrates, which include samarium, europium, gadolinium, terbium, dysprosium, and others; and SorbX, a line of proprietary rare earth-based water treatment products.
Why Should Investors Buy MCP After the Recent Fall? Just Go Here and Find Out
Keryx Biopharmaceuticals (NASDAQ:KERX)’s shares dropped -1.47 percent from its previous close of $12.94 to close at $12.75. The stock is up around 386.64% this year and 306.05% for the last 12 months. Around 3.82 million shares changed hands yesterday, higher from an-average trading volume of 3.31 million shares. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes.
Will KERX Get Buyers Even After The Recent Rally? Find Out Here
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Read full disclaimer at: http://otcstockpicks.net/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)